Home » Topics » Ocular, BioWorld Science

Ocular, BioWorld Science
RSS

ISTA Pharmaceuticals' Vitrase granted three-year market exclusivity

Sep. 23, 2004

The EMEA accepts marketing authorization application for Macugen

Sep. 23, 2004

Approvable letter for Extravan for glaucoma

Sep. 21, 2004

Novel VAP-1 inhibitors and their use in macular edema described by Fujisawa

Sep. 15, 2004

Sirna Therapeutics files IND to advance Sirna-027 into clinic

Sep. 9, 2004

Gatiflo eye drops launched in Japan

Sep. 8, 2004

Macugen NDA accepted for review

Aug. 23, 2004

Pfizer scientists describe new antiangiogenic agents for ocular disorders

Aug. 19, 2004

Acuity files IND for phase I trials of Cand5

Aug. 16, 2004

Approvable letter for ZyLET

Aug. 11, 2004

Popular Stories

Today's news in brief
BioWorld
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...